Objective: In women with Human Epidermal growth Receptor 2 (HER2)positive metastatic breast cancer (MBC), Trastuzumab has become the standard of care but previous studies have raised doubts about its economic acceptability. We carried out the first cost-effectiveness study for Trastuzumab in MBC patients, in France, that is based on observed resource use and outcomes in clinical practice. Methods: We retrospectively analyzed 47 HER2-positive MBC patients in a before-and-after design study. Nineteen patients did not receive Trastuzumab ("before" Trastuzumab introduction in clinical practice) and 28 patients received Trastuzumab (the "after" population). Direct medical costs were estimated on the basis of the physical quantities reported in the patient medical records, for the period from first metastatic progression until death or date of patient last news. Monetary values (2002 French francs) were attributed to these quantities on the basis of unit costs and incremental cost-effectiveness ratios were calculated. Results: In the Trastuzumab group, median overall survival was significantly higher (37 months vs. 19 months in the non-Ttrastuzumab group, P ϭ 0.001) but total treatment costs were 3 times higher (€39,608 vs. €12,795). The cost per additional life-year saved by Trastuzumab treatment was estimated to be €27,492 (95% confidence interval: €20,964-€34,020/year of life [bootstrapped estimation]). Conclusions: Our data suggest that despite its high unit price, Trastuzumab should be considered cost-effective in MBC patients to the extent that its incremental cost per life-year saved remains lower than gross domestic product per capita in countries like France.
B reast cancer remains the leading cause of cancer deaths in western countries and therefore represents a major health public issue. In addition to the continuous development of conventional cytotoxic anticancer drugs for breast cancer treatment, significant progress has occurred in recent years about the scientific knowledge of tumor biology, leading to the identification of new molecular targets. v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), also called HER2 or Neu, belongs to the ERBB family of tyrosine kinase receptor. These transmembrane proteins with signaling activities play significant roles in various critical cellular processes, including proliferation, cell survival, differentiation, angiogenesis, or invasion/motility. 1 ERBB2 overexpression, which essentially results from gene amplification and is observed in 20% to 30% of breast cancers, 2 is associated with a poor prognosis. 3, 4 Trastuzumab (Herceptin), a humanized monoclonal antibody directed against the extracellular domain of ERBB2 was approved by the US Food and Drug Administration, and ultimately by the European authorities, in 2000 for treatment of metastatic breast cancer (MBC) overexpressing ERBB2, as detected either by immunohistochemistry (IHC) or by fluorescence in situ hybridization (FISH). In combination with chemotherapy, Trastuzumab has been shown to significantly improve response rates, progression-free and overall survival (OS) in MBC patients. 5, 6 Recent evidence suggests that it also improves the outcome of ERBB2 positive early breast cancer, when administered in the adjuvant setting. [7] [8] [9] Trastuzumab is a typical example of recent developments in biotechnology leading to a new kind of cancer therapies known as selective gene targeted therapies. 10 The massive and innovative R and D efforts devoted to the discovery and testing of monoclonal antibodies like Trastuzumab (Herceptin) have justified high market prices for this product, which in turn have contributed to a significant increase of treatment costs for the targeted patients. 11 Previous economic evaluations have therefore found rather high cost-effectiveness ratios, 11 and one of the authors even concluded that "Trastuzumab is not cost effective in MBC." 12 All these cost-effectiveness analysis (CEA) have however been based on simulation models using empirical data from various sources including the clinical literature. We therefore performed a retrospective economic evaluation comparing the Trastuzumab administration (vs. no administration) in a homogeneous population of MBC patients who over-expressed-HER2, and who were treated in the same French oncology department just before and after the introduction of Trastuzumab in clinical practice. In the current context, where all governments from Organization for Economic Co-operation and Development countries implement policies to limit the escalation of health care expenditures, such analysis may contribute to the on-going debates about the diffusion of innovative but costly cancer drugs like Trastuzumab.
PATIENTS AND METHODS

Study Population and Clinical Data
We retrospectively analyzed medical files and cost data about all patients (n ϭ 47) with breast tumors who were treated for first metastatic progression (MP), at the Regional Cancer Hospital of Marseilles in South Eastern France (Institut Paoli-Calmettes ͓IPC͔) between January 1st, 2000 and August 31st, 2004. To enter the current study, patients with metastatic disease, defined like a remote identifiable site, were required to over-express ERBB2 as detected by IHC (3ϩ) and/or to present ERBB2 amplification as detected by FISH, evaluated either on primary site or on distant metastasis.
We used an after-and-before design, in which "before" refers to a measurement made before the introduction of Trastuzumab in clinical routine and after refers to a measurement made after its introduction. All patients received standard chemotherapy but the first 19 patients did not yet receive Trastuzumab, whereas the following 28 patients benefited from the new drug. To identify retrospectively the 19 ERBB2 positive MBC patients (the no-Trastuzumab group), IHC was carried out in anatomy-pathologic samples of 192 MBC patients treated in the hospital just before the introduction of Trastuzumab.
Clinical data collected at diagnosis were presented in Table 1 Patients treated with Trastuzumab received a loading dose of 4 mg/kg followed by weekly doses of 2 mg/kg until progression or for a maximum duration of 1 year in case of response. Trastuzumab treatment has been administered as single agent after intensive or standard chemotherapy, or in combination to chemotherapy (taxanes). The no-Trastuzumab group received standard cytotoxic treatment of MBC (taxanes and/or anthracycline based chemotherapy).
Two clinical endpoints were used: progression-free survival (PFS) (time between diagnosis of the first MP to the second MP) and overall survival (time from diagnosis of the first MP to the last follow-up visit).
Data Collection and Methodology for Assessment of Treatment Costs
The cost analysis was limited to direct medical costs for the hospital but this certainly encompasses the quasi totality of treatment costs for the French health care system in the case of such patients. First, individual patient records were used to obtain detailed data about resource utilization in physical quantities from the date of the first MP until the date of patient's last follow-up. The following cost factors were analyzed: Only some pharmacy costs (growth factors, chemotherapy, and Trastuzumab costs excepted) and costs of immunohistochemical assays and/or FISH to identify candidates for Trastuzumab treatment were omitted from our analysis.
For 3 patients, we could not obtain detailed observation of the cost factors. These 3 missing data in the total cost were replaced by the mean of the other patients cost factors (mean replacement).
Monetary values were subsequently associated with each of the physical quantities consumed on the basis of unit costs, using the accounting system of the IPC which is managed according to the rules of the French public health care sector. All monetary values were expressed in constant €2002.
Because of the well-identified problem of differences between hospital charges and real costs, 13 especially in the context of a publicly funded health care system as the French one, hospital charges were not used for assessing monetary values associated with patient stay in different units. The per diem "real cost" for each hospitalization unit was an average cost calculated from data collected at the IPC. The annual expenditures for consumable supplies, cost for personnel in the unit, food cost and depreciation of equipment (depreciation rate of 20%) were collected in the analytic accounts of this center to calculate the per day clinic costs for each stay in every unit.
Step-down methodology was used to add overheads to these units. 14 Drug prices were the purchase prices nationally negotiated by the Federation of French Cancer Hospitals (€2001). Concerning the packaging of drugs, we made the assumption that every vial opened was consumed (unused drug in opened vials was discarded). Costs of the various medical procedures in France are established each year by the Social Security (Health Care Financing Administration) at the national level, based on a system of points. We used this price list to evaluate the cost of imagery tests. For unit costs of collection procedure for stem cells, monetary values were obtained from a parallel study of 112 patients collected in the same hospital. 15 The CEA was performed by the calculation of an incremental cost-effectiveness ratio (ICER) defined as extra costs of the Trastuzumab group versus the no-Trastuzumab group per additional unit of clinical effectiveness.
Statistical Analysis
Patients' characteristics, clinical data, and cost factors expressed in physical units were compared using the 2 test for categorical data and the Student t test for normally distributed quantitative variables. As they had not been normally distributed, costs data were compared using the Mann-Whitney nonparametric test.
Survival interval was calculated from day of first MP until death, whatever the cause; PFS was calculated from time of metastasis diagnosis until progression occurrence or death. Patients were censored at time of last follow-up. Progression probability was determined by cumulative incidence whereas Kaplan-Meier determinations were used to estimate survival probabilities and PFS. 16 Survival curves were compared by the log-rank test. 17
Uncertainty of the Cost-effectiveness Ratio
Sensitivity Analysis
A bivariate sensitivity analysis (SA) was performed on 2 parameters used in the based-case analysis: Trastuzumab unit cost and hospitalization unit cost. The current development of alternative molecules with a similar target than Trastuzumab and the fact that Trastuzumab is a pharmacogenomic innovation that benefited from initially high levels of price, support the hypothesis that its price may decrease in the future. Thus the SA was performed on a reduction of Ϫ25%, Ϫ50%, and Ϫ75% of Trastuzumab unit cost. In parallel, we varied the hospitalization unit cost of Ϯ50% in the analysis to take into account potential uncertainties in the estimation of this cost.
Bootstrapping of the Cost-effectiveness Ratio
To fully explore the uncertainty in the estimates of incremental cost-effectiveness ratio, we used a bootstrapping method. An observation sample (with the same size that the original sample) was randomly drawn from the original sample for cost and effectiveness for each group of treatment 1000 times. Thus, 1000 mean costs and 1000 mean end-points associated were obtained for each study groups, leading to 1000 ICER. The confidence interval was then obtained by taking observation at 2.5 and 97.5 percentile.
RESULTS
Characteristics of the 2 patients groups (with and without Trastuzumab) are described in Table 1 : no significant difference was found for age at diagnosis, number of axillary nodes, hormonal receptors, presence of synchronous metastasis on diagnosis, and median disease-free interval. Figure 1 shows a significant increase in OS for the Trastuzumab group (median survival ϭ 37.02 months ͓95% confidence interval {CI}: 28.71-45.34͔ vs. 18.98 months ͓95% CI: 3.84 -34.11͔ in the no-Trastuzumab group) (P Ͻ 0.001, log-rank test). The median survival without progression was also higher in the Trastuzumab group (11, 54 months ͓95% CI: 3.31-19.77͔ vs. 7.97 months ͓95% CI: 3.31-19.77͔), although this difference did not reach statistical significance (P ϭ 0.283) (Fig. 2) .
Not surprisingly, direct medical costs of treatment were nearly tripled in the Trastuzumab group (€39,607 on average vs. €12,795), as shown in Table 2 . It must also be noted that the contribution of each specific cost factor to the total cost of treatment is quite different in the 2 groups: costs related to the high unit price of Trastuzumab account for more than 40% of total expenditures in the Trastuzumab group whereas room costs related to the duration of hospitalization remain the most important cost factor (60%) in the no-Trastuzumab group. The observed difference between both groups in room costs and imagery tests are certainly related with the specific modalities of Trastuzumab administration. First, imagery tests were nearly tripled in the Trastuzumab group (€2343 vs. €727). This increase must be related to the constraints of Trastuzumab administration which impose a left ventricular systolic function every 2 months. Second, Trastuzumab was administered on a weekly basis in an outpatient hospital logically implying an increase in hospitalization costs for the group who benefited from this treatment (€10,662 vs. €7273). Table 3 shows that direct medical costs of treatment between the first to the second MPs were nearly quadrupled in the Trastuzumab group (€26,886 on average vs. €6512). Costs related to the price of Trastuzumab account for 50% of total expenditures in the Trastuzumab group whereas room costs related to the duration of the hospitalization remain the most important cost factor (46%) in the no-Trastuzumab group. Like previously, the increase in room costs (€6546 vs. €2968) and imagery tests (€1602 vs. €528) was certainly related to the constraints of Trastuzumab administration. It must also be noted in Table 3 that costs of chemotherapy regimens were quite identical in both groups between the first to the second MPs. The fact that overall costs of chemotherapy are slightly higher in the Trastuzumab group (Table 2) was clearly related to the fact that these patients survive longer and consequently necessitate treatment for a longer period.
The CEA shows that the ICER was €17,800 per year of life (yol) saved and €69,111 per yol saved, respectively, without MP. Bootstrapped estimates of ICER were respectively 27,492 per yol saved (95% CI: 20,964 -34,020/yol) and €81,828 per yol saved without MP (95% CI: 56,400 -107,256). Figure 3 details the estimates of the ICER per yol saved when simultaneously taking into account alternative unit costs for Trastuzumab and hospitalization room costs. Figure 3 shows that under all assumptions about the values of these 2 key parameters of total costs of treatment the cost per additional yol saved always remains higher than €8000/yol but lower than €20,000/yol. When a similar SA is performed about the ICER per yol saved without MP, the costeffectiveness estimates vary from a minimum of €28,450/yol to a maximum of €74,500/yol.
DISCUSSION
In women with HER2-positive MBC, Trastuzumab has become the standard of care, and is now licensed for use in combination with paclitaxel (Europe and the United States) or docetaxel (Europe). Rapid diffusion of Trastuzumab is related to the clear evidence that its use of improves clinical effectiveness in MBC patients. 18 However, there have been concerns that because of its high acquisition cost, such pharmacogenomic innovation may increase total costs of treatment in even greater proportions leading to a debate about the economic acceptability of diffusion of Trastuzumab in the current context of health care systems. 19, 20 Indeed, there is a growing consensus world-wide that cost-effectiveness considerations should be taken into account when making private or public health insurance decisions for coverage of innovative and costly medical procedures. 21 However, the threshold value that should be considered acceptable 22 Many economists will nevertheless argue that investment in health improvements which produce an additional "statistical" life-year for less than 2 of 3 times the gross domestic product per capita (ie, between €54,000 and €71,000 in the case of France in 2005) remain highly profitable for society. [21] [22] [23] There had been only 2 previous CEA, 1 carried out in Belgium, 11 the other one in Norway, 12 about Trastuzumab in MBC. Their results estimated the cost per additional life-year saved because of the use of Trastuzumab circa €48,000 in the Belgian case and in the range €63,000/€147,000 in the Norwegian context, that is to say between €20,000 and €120,000 more than our estimation. Such cost-effectiveness ratios may or may not be deemed acceptable depending on the threshold values that are considered appropriate for allocating resources in the health care sector. It must however be emphasized that these previous studies were based on simulation exercises, whereas our study was only based on a detailed observation of patients records. The Belgian and Norwich study aggregated clinical data from various sources, including the literature, with actual cost data collected about patients in each national context. One practical reason for using simulation came from the fact that identification of ERBB2-positive MBC has been related to avail-ability of Trastuzumab and that it was quite difficult to get real data about the control group of non-Trastuzumab treated patients presenting this genetic characteristic.
To our knowledge, our study carried out retrospectively in a French cancer hospital was the first to estimate the costeffectiveness of Trastuzumab in a homogeneous population of ERBB2-positive MBC patients treated in a similar fashion and context with the only difference that 1 group had not yet benefited from Trastuzumab and the other did (before and after study design). Our results confirm the facts already established by the previous studies: Trastuzumab significantly improves OS in MBC patients at the expense of a significant increase in total costs. It should be noted that our cost estimates took into account costs of chemotherapy in case of a second MP had occurred. However, results of our study clearly contrast with those of previous CEA to the extent that our estimate of the cost per life-year saved is lower than €30,000 making this innovation economically feasible under all hypotheses.
Of course, some limitations of our study should be acknowledged. First, some cost categories were not taken into account in our estimates. In particular, costs of pharmacy (growth factors, chemotherapy and Trastuzumab excepted) have been omitted from our study and considered as negligible. Actually, a previous study estimated these cost as representing less that 2% of the total cost per patient treated. 12 Costs of immunohistochemical assays and/or FISH to identify candidates for Trastuzumab treatment have also been omitted although far from being negligible. 24, 25 However, this is not very likely to change our conclusion: one of the 2 previous CEA 11 -50% -25% 0% 25% 50% -75% -25% 0 suggested that adding the costs of FISH would only increase the ICER in the range of €700. Second, the before-and-after design presents some threats to internal validity, especially the "history threat." A "history threat" occurs when 1 or more events, which are not part of the intervention but could affect the outcome, takes place between the "before" and "after" measurements (changes in the management personnel; work processes, structure or pace; legislation). Clearly, the very short time between the "before" and "after" measurements in our study made negligible the opportunity for an extraneous interfering event to happen.
Finally, because our study was retrospective, we could not collect data about patients' quality of life (qol) through interviews or questionnaires. However, this lack of data rather tends to underestimate benefits associated with Trastuzumab therapy because it has been showed that Trastuzumab adds little to the toxicity profile of chemotherapy agents and that Trastuzumab combination therapy are associated with improvements in qol when compared with chemotherapy alone. 26 -28 Of course, when we recalculated the ICER using time without MP as an alternative clinical effectiveness end point, the ICER per life-year saved logically increased to a higher €56,400 to €107,256 range. This estimate should, however, not be misinterpreted to the extent that such end point de facto gives no value at all to the additional 14 months of survival in the Trastuzumab group that these patients spent with a second MP. If one makes the quite drastic assumption that qol associated with time spent with a second MP is only half of that experienced with remission, the ICER of Trastuzumab is circa €29,250 per quality adjusted life-year, which can be considered reasonable even with the most stringent threshold values.
Finally, the main limitation of our study comes from the relatively small number of patients included in the evaluation that may raise some concerns about the statistical power of our comparison. As already mentioned, it was quite difficult to identify retrospectively MBC patients who would have been eligible for Trastuzumab treatment but did not yet get access to it because of the timing of authorization of this new drug in France. Our study was the first CEA to be able to include a control group of this kind. Moreover, although our results were derived from a limited sample size study with the above mentioned limitations, we believe they are likely to be generalizable to MBC patients receiving Trastuzumab in clinical practice across France for the following reasons: first, the population study (ERBB2 positive MBC receiving Trastuzumab-based firstline treatment) was representative of the majority of patients routinely treated with Trastuzumab in this setting in the country Second, the PFS and OS obtained in this study were very similar to those reported in controlled trials investigating Trastuzumabbased treatment in this setting. 5 Finally, patients were all treated in a comprehensive cancer center with a recognized position at the national level, making it highly representative of standard of care in this disease.
Pharmacogenomics has recently emerged as a field aimed at identifying inherited factors that may predict interindividual variations in drug efficacy and toxicity and it raises great hopes that it could contribute to providing cost-effective care 29, 30 : by better identifying patients whose genetic characteristics of tumors make them more responsive to a specific treatment. Pharmacogenomics has the potential to stop the law of diminishing returns (regular increase in marginal costs to obtain 1 additional unit of clinical benefit) that has characterized most innovations in oncology treatments up to now. Trastuzumab is 1 of the prototypical examples of the application of genomic technologies to cancer treatment and it is quite significant that its cost-effectiveness has been questioned in parallel to its first application in MBC patients. The debate about its cost-effectiveness is now extending as Trastuzumab use in the adjuvant setting. 31 Our study helps clarifying this debate by providing some evidence based on real directly observed data that Trastuzumab are indeed cost-effective for treatment of MBC. It suggests that similar CEA should be carried out for the other clinical indications of Trastuzumab.
